Identification of human and rabbit cytochromes P450 1A2 as major isoforms involved in thiabendazole 5-hydroxylation

被引:22
作者
Coulet, M
Dacasto, M
Eeckhoutte, C
Larrieu, G
Sutra, JF
Alvinerie, M
Macé, K
Pfeifer, AMA
Galtier, P
机构
[1] INRA, Lab Pharmacol Toxicol, F-31931 Toulouse, France
[2] Univ Turin, Dipartimento Patol Anim, Settore Farmacol & Tossicol, I-10124 Turin, Italy
[3] Nestec Ltd, Nestle Res Ctr, CH-1000 Lausanne, Switzerland
关键词
thiabendazole; metabolism; cytochromes P450; hepatocytes; human cell lines; drug-drug interactions;
D O I
10.1111/j.1472-8206.1998.tb00946.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This report characterized one of the major cytochrome P450 isozyme involved in thiabendazole metabolism. This study was undertaken by using both cultured rabbit hepatocytes treated or not with drugs known to specifically induce various cytochromes P450 isoenzymes (ie, P450 1A1/2 by beta-naphthoflavone, P450 2B4 by phenobarbital, P450 3A6 by rifampicine and P450 4A by clofibrate) and human liver (THLE-5) and bronchial (BEAS-2B) epithelial cells expressing or not the major constitutive human cytochromes P450 (ie, CYP1A2, 2A6, 2B6, 2C9, 2D6, 2E1 or 3A4). Only hepatocytes exposed to beta-naphthoflavone and clofibrate significantly metabolized thiabendazole to 5-hydroxythiabendazole. Extensive biotransformation of this anthelmintic only occurred in human cells expressing CYP1A2. Moreover, experiments performed on rabbit preparations showed good correlations between thiabendazole 5-hydroxylase activity and both ethoxyresorufin and methoxyresorufin O-dealkylase activities. Thus, CYP1A2 is a major isoenzyme involved in thiabendazole 5-hydroxylation. (C) 1998 Elsevier, Paris.
引用
收藏
页码:225 / 235
页数:11
相关论文
共 44 条
[1]   THIABENDAZOLE IS AN INDUCER OF CYTOCHROME P4501A1 IN CULTURED RABBIT HEPATOCYTES [J].
AIX, L ;
REYGROBELLET, X ;
LARRIEU, G ;
LESCA, P ;
GALTIER, P .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1994, 202 (03) :1483-1489
[2]  
ALVINERIE M, 1991, ANALUSIS, V19, P224
[3]  
BARCELO S, 1997, IN PRESS MUT RES
[4]   THE PHARMACOKINETICS OF THIABENDAZOLE AND ITS METABOLITES IN AN ANEPHRIC PATIENT UNDERGOING HEMODIALYSIS AND HEMOPERFUSION [J].
BAUER, LA ;
RAISYS, VA ;
WATTS, MT ;
BALLINGER, J .
JOURNAL OF CLINICAL PHARMACOLOGY, 1982, 22 (5-6) :276-280
[5]  
Bergmeyer H.U., 1963, METHOD ENZYMAT AN, P736
[6]   CYTOCHROME-P450 SPECIFICITIES OF ALKOXYRESORUFIN O-DEALKYLATION IN HUMAN AND RAT-LIVER [J].
BURKE, MD ;
THOMPSON, S ;
WEAVER, RJ ;
WOLF, CR ;
MAYER, RT .
BIOCHEMICAL PHARMACOLOGY, 1994, 48 (05) :923-936
[7]  
COCHIN J, 1959, J PHARMACOL EXP THER, V125, P105
[8]  
Darbyshire JF, 1996, DRUG METAB DISPOS, V24, P1038
[9]   EXPRESSION OF 5 FORMS OF MICROSOMAL CYTOCHROME-P-450 IN PRIMARY CULTURES OF RABBIT HEPATOCYTES TREATED WITH VARIOUS CLASSES OF INDUCERS [J].
DAUJAT, M ;
PICHARD, L ;
DALET, C ;
LARROQUE, C ;
BONFILS, C ;
POMPON, D ;
LI, D ;
GUZELIAN, PS ;
MAUREL, P .
BIOCHEMICAL PHARMACOLOGY, 1987, 36 (21) :3597-3606
[10]   INTRAHEPATIC CHOLESTASIS AFTER THIABENDAZOLE [J].
DAVIDSON, RN ;
WEIR, WRC ;
KAYE, GL ;
MCINTYRE, N .
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 1988, 82 (04) :620-620